CD22 and acute lymphoblastic leukemia: In an early phase 1 study, one group in Guangdong, China plans to assess sequential treatment with either CD20-, CD22- or CD10-CAR T cells following CD19-CAR T therapy in 30 patients in the R/R B-ALL setting (NCT03407859).